[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366661-105":59,"doc-detail-366661-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","epigenetic-regulation-in-gynecological-cancers-a-paradigm-shift-in-immunotherapy-strategies","Epigenetic regulation in gynecological cancers - a paradigm shift in immunotherapy strategies","","Immunotherapy has reshaped treatment for gynecological cancers, yet durable responses are limited by tumor heterogeneity and immune evasion. Epigenetic modifications, including DNA methylation, histone modifications, and RNA methylation, act as key regulators of the tumor immune microenvironment and immunotherapy efficacy. This review analyzes how epigenetic alterations affect immune cell infiltration, antigen presentation, immune checkpoint expression, and tumor immunogenicity across cervical, ovarian, and endometrial cancers. It also discusses roles of epigenetic enzymes (DNMTs, HDACs, BET, and RNA methyltransferases) and the therapeutic value of targeting these regulators to sensitize tumors to immune checkpoint inhibitors, cancer vaccines, cytokine-based treatments, and adoptive T-cell therapies. Preclinical and clinical evidence is synthesized for combining DNMT and HDAC inhibitors with immunotherapies to overcome immunoresistance, supporting a precision immunoepigenetic paradigm for improved outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/epigenetic-regulation-in-gynecological-cancers-a-paradigm-shift-in-immunotherapy-strategies/366661/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/epigenetic-regulation-in-gynecological-cancers-a-paradigm-shift-in-immunotherapy-strategies/366661.png","ImageObject",300,407,{"name":92,"@type":93},"Blitz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How does immunotherapy differ for gynecological cancers, and what limits durable responses?","Question",{"text":113,"@type":114},"Immunotherapy has transformed the treatment landscape, but durable responses are limited by tumor heterogeneity and immune evasion mechanisms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which epigenetic modifications are highlighted as regulators of the tumor immune microenvironment?",{"text":118,"@type":114},"The review emphasizes DNA methylation, histone modifications, and RNA methylation as pivotal regulators of the tumor immune microenvironment and immunotherapy efficacy.",{"name":120,"@type":111,"acceptedAnswer":121},"How do epigenetic changes influence chemoresistance in these cancers?",{"text":122,"@type":114},"Epigenetic processes can contribute to chemoresistance by silencing tumor suppressor genes, enhancing drug efflux, and disrupting DNA repair.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},366661,1790834429,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":24,"preview_urls":147},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Zhao et al. J Exp Clin Cancer Res (2025) 44:275 [https://doi.org/10.1186/s13046-025-03509-1](https://doi.org/10.1186/s13046-025-03509-1)  \nJournal of Experimental & Clinical Cancer Research  \n REVIEW Open Access  \nEpigenetic regulation in gynecological   cancers: a paradigm shift in immunotherapy strategies  \nChenyuan Zhao1, Yang Liu 1 and Zhuo Cui1*  \nAbstract  \nRecent advances in immunotherapy have transformed the therapeutic landscape of gynecological cancers; however, durable responses remain limited by tumor heterogeneity and immune evasion mechanisms. Emerging evidence highlights epigenetic modifications comprising of DNA methylation, histone modifications, and RNA methylationas pivotal regulators ofthe tumor immune microenvironment and immunotherapy efficacy. This review comprehensively explores how these epigenetic alterations modulate immune cell infiltration, antigen presentation, immune checkpoint expression, and tumor immunogenicity across cervical, ovarian, and endometrial cancers. We also delineate the impact of specific epigenetic enzymes, such as DNMTs, HDACs, BET and RNA methyltransferases, in shaping immune responses and discuss the therapeutic potential of targeting these regulators to sensitize tumors to immune checkpoint inhibitors, cancer vaccines, cytokine based treatments and adoptive T-cell therapies. Furthermore, we examine the integration of epigenetic agents such as DNMT and HDAC inhibitors with immunotherapies in preclinical and clinical settings, emphasizing their synergistic capacity to overcome immunoresistance. By illuminating the interplay between epigenetic regulation and immune dynamics, this review underscores a paradigm shift toward precision immunoepigenetic strategies, offering a promising framework for enhancing therapeutic outcomes in gynecological malignancies.  \nKeywords Epigenetic, Gynecological cancer, Immunotherapy, TIME  \n*Correspondence: Zhuo Cui [zcyhldsyy@163.com](zcyhldsyy@163.com)  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativecom](http://creativecom)[mons.org/publicdomain/zero/1.0/](mons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nZhao et al. J Exp Clin Cancer Res (2025) 44:275 Page 2 of 43  \nGraphical Abstract  \nIntroduction  \nGynecological cancers, ovarian, cervical, and endometrial, pose significant challenges due to their molecular complexity, aggressive behavior, and therapy resistance. These cancers drive global morbidity and mortality through genetic and epigenetic alterations that promote tumor growth and immune evasion [1]. Ovarian cancer, the deadliest of these, has a 5-year survival rate of 47%. Only 15% of cases are diagnosed early, and despite surgery and platinum-based chemotherapy, most patients relapse within three years, with 25% showing platinum resistance at first relapse. Alternat","cbCairRJcTQIFXd6","https://ap.wps.com/l/cbCairRJcTQIFXd6","pdf",2377076,43,"English","# Introduction\n## Background and clinical challenges in ovarian, cervical, and endometrial cancers\n## Epigenetic mechanisms and their impact on the tumor immune microenvironment (TIME)\n# Epigenetic regulation and therapy resistance\n## DNA methylation and histone modification effects on chemoresistance\n## Cancer-type examples: ovarian, cervical, and endometrial\n# Epigenetic mechanisms and immunotherapy outcomes\n## Effects on immune infiltration, antigen presentation, and checkpoints\n## Targeting epigenetic enzymes to enhance immunotherapy\n# Combination strategies and paradigm shift\n## DNMT/HDAC inhibitors with immunotherapies in preclinical and clinical settings","[{\"question\":\"How does immunotherapy differ for gynecological cancers, and what limits durable responses?\",\"answer\":\"Immunotherapy has transformed the treatment landscape, but durable responses are limited by tumor heterogeneity and immune evasion mechanisms.\"},{\"question\":\"Which epigenetic modifications are highlighted as regulators of the tumor immune microenvironment?\",\"answer\":\"The review emphasizes DNA methylation, histone modifications, and RNA methylation as pivotal regulators of the tumor immune microenvironment and immunotherapy efficacy.\"},{\"question\":\"How do epigenetic changes influence chemoresistance in these cancers?\",\"answer\":\"Epigenetic processes can contribute to chemoresistance by silencing tumor suppressor genes, enhancing drug efflux, and disrupting DNA repair.\"}]","Epigenetic regulation in gynecological cancers - a paradigm shift in immunotherapy strategies | PDF",1790166616,108,[148,152,156,160,164],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa0c7acf34b7d9529fbf81e109ab4225.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11d0418c6189ad41c3f732804ace6745.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fc93a911ecff0bb7bad34fbec7f65ac.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c1043b3cf6cd00c759297be0b13d3b2.webp",980,1301,{"page_no":24,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c47ded14feca881798f0e65a97bc0ce.webp",979,1300]